Child pages
  • Asthma in the EU: Recommendations for EU action
Skip to end of metadata
Go to start of metadata
Subject: Asthma in the EU: Recommendations for EU action
Date sent: 29 November 2007

Message:

On 20th November the Brussels Declaration signatories, including the IPCRG, launched a new report by the Centre for European Policy Studies (CEPS) Asthma in the EU: towards better management and regulation of a public health issue. http://www.theipcrg.org/news/index.php It helps identify what actions can be done at a Europe-wide level and what require national attention.  It concludes that the most scope for improvement at European  level is through 4 things:

  1. Influencing the European Medicines Agency (EMEA) process for assessment of medicinal products, such as asthma therapy, which “ lackstransparency and fails to involve relevant stakeholders such as patient and clinician representatives in a formalised way.  
  2. Improving the monitoring of post-approval adverse reactions, known as pharmacovigilance, so that it captures real-life situations where much care is self-managed.
  3. Supporting member states to identify best practice through the Open Method of Coordination (OMC); this might enable best practice such as the Finnish model, to be shared across member states.
  4. Communicating best  practice through methods such as disease-specific fact sheets.


Siân Williams, Executive Officer

29th November 2007

 
 
  • No labels